Pulmonary Fibrosis

Latest News

Beyond well-characterized cellular and molecular pathways, the authors explore the emerging significance of non-coding RNAs. | Image credit: PRASANNAPIX - stock.adobe.com
Insights Into Pulmonary Fibrosis Pathogenesis, Treatments, and the Potential Role of Traditional Chinese Medicine

August 5th 2025

From alveolar injury to extracellular matrix accumulation, the complex biology of pulmonary fibrosis is being unraveled alongside explorations of both Western and traditional Chinese therapies.

The investigators said they believe their scoring system to be a useful tool that will improve patient care. | Image Credit: mi_viri
AIM-30 Score Predicts Mortality Following Acute Exacerbation of IPF

July 30th 2025

IPF and PPF both face poor survival rates, and the pair share similar clinical features, leading to similar treatment approaches, which are limited and nuanced. | Image credit: Sebra - stock.adobe.com
Setting Care Goals Early Is Key in Pulmonary Fibrosis

July 29th 2025

The findings showed that certain IPF phenotypes had a significant association with hypothyroidism. | Image credit: surasak - stock.adobe.com
Immune Cell Phenotypes Linked With Hypothyroidism, IPF

July 23rd 2025

Genomics and metabolomics have sparked an opportunity to find biomarkers that might make it easier to diagnose idiopathic pulmonary fibrosis at an earlier stage. | Image credit: PRASANNAPIX - stock.adobe.com
Metabolites With Potential Role in IPF Identified by Genome-Wide Association Study

July 9th 2025

Advancing IPF Care: New Evidence and Economic Considerations in Treatment Decision-Making

Learn about the clinical and economic burden of idiopathic and progressive pulmonary fibrosis; the need for earlier diagnosis and improved care coordination; and emerging therapies that may close treatment gaps.

AJMC Peer Exchange logo displayed on a blue geometric background with layered diamond shapes.

More News

Young man coughing | Image Credit: © Tetiana - stock.adobe.com
September 18th 2024

Chronic Cough in Patients With ILD Linked to Reduced Quality of Life

Kimberly Rath, PharmD
Findings of a systematic review highlight the need for standardized assessment tools and targeted treatments for chronic cough in patients with idiopathic pulmonary fibrosis and other interstitial lung diseases.
IPF wooden blocks | Image Credit: Sviatlana - stock.adobe.com
September 15th 2024

Automated Body Composition Analysis Predicts Survival in IPF

Jared Kaltwasser
Researchers say machine learning advances make it possible to use more sophisticated body composition analyses to assess risk of mortality from idiopathic pulmonary fibrosis (IPF).
Clinical trial graphic | Image credit: photon_photo – stock.adobe.com
September 10th 2024

Overcoming Failures: Lessons From IPF Clinical Trials in the Past Year

Hayden E. Klein
Luca Richeldi, MD, PhD, outlined crucial lessons from recent idiopathic pulmonary fibrosis (IPF) trial failures, advocating for adaptive trial designs, rigorous statistical methods, and a focus on patient-relevant outcomes to enhance future research.
AI image of lung fibrosis | Image credit: Oranuch – stock.adobe.com
September 8th 2024

New Findings Highlight the Impact of Lung Function Decline in IPF, PPF

Hayden E. Klein
A pair of studies presented at the European Respiratory Society Congress 2024 emphasized the importance of close monitoring and proactive treatment approaches for patients with idiopathic (IPF) and progressive pulmonary fibrosis (PPF).
Martin Kolb, MD, PhD
August 30th 2024

Helping Patients Understand IPF Diagnosis and Treatment

Hayden E. Klein
Martin Kolb, MD, PhD, highlights the importance of taking time to explain the complexities of idiopathic pulmonary fibrosis (IPF) to patients before starting long-term treatment.
BMI scale | Image credit: Olivier Le Moal – stock.adobe.com
August 22nd 2024

Higher BMI May Decrease Death Risk for Patients With IPF

Hayden E. Klein
New findings point to a 6% decrease in mortality risk for each unit increase in body mass index (BMI).
Martin Kolb
August 16th 2024

Dr Martin Kolb: Addressing IPF Mortality and Costs Through Timely Intervention

Hayden E. Klein
Early intervention for idiopathic pulmonary fibrosis (IPF) is crucial due to the high mortality rate, with emerging therapies like nerandomilast showing potential to reduce health care costs by preventing disease progression.
Three distinct blood biomarker signatures were associated with lung function and prognosis in pulmonary fibrosis. | Image credit: meeboonstudio-stock.adobe.com
August 13th 2024

Blood Biomarker Analysis Identifies Distinct Endotypes in Pulmonary Fibrosis

Rose McNulty
The identification of unique pulmonary fibrosis endotypes is an important step in the development of precision medicine approaches for the incurable condition.
Martin Kolb, MD, PhD
August 1st 2024

Exploring Nerandomilast's Value in the Complex IPF Treatment Landscape

Hayden E. Klein
Martin Kolb, MD, PhD, discusses the challenges of treating idiopathic pulmonary fibrosis (IPF) and highlights the potential benefits of a new PDE4B inhibitor, nerandomilast.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Therapeutic Response and Disease Progression

Justin Oldham, MD, MS
An expert on idiopathic pulmonary fibrosis describes the therapeutic response of standard-of-care treatments and how multidisciplinary care can be optimized when treating patients.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Current Standard of Care in IPF

Justin Oldham, MD, MS
Justin Oldham, MD, MS, discusses the current standard of car in treating idiopathic pulmonary fibrosis and the role of non-pharmacologic therapies.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Advice for Clinicians Treating IPF

Steven D. Nathan, MD
Dr Nathan provides his final thoughts regarding IPF management.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Future Possibilities in IPF Treatment

Steven D. Nathan, MD
Dr Nathan discusses the trajectory of IPF management.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Importance of Patient-Reported Outcomes

Steven D. Nathan, MD
Steven Nathan, MD, continues a discussion surrounding the patient journey in through IPF treatment.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

IPF and PDE4B Inhibitors

Steven D. Nathan, MD
Dr Nathan highlights the role of PDE4B inhibitors in IPF management.
Justin Oldham, MD, MS, an expert on IPF
August 1st 2024

Emerging Agents in IPF Treatment

Steven D. Nathan, MD
Steven Nathan, MD, discusses breakthrough treatments for idiopathic pulmonary fibrosis.
Patient pouring pills into hand | Image credit: doucefleur – stock.adobe.com
July 24th 2024

Patient Response to Pirfenidone, Nintedanib for IPF Differs in Real World vs Trials

Hayden E. Klein
While both drugs slowed down lung function decline in idiopathic pulmonary fibrosis (IPF), they were also linked to more deaths and increased incidence of acute exacerbation of IPF in real-world settings.
Doctor holding piggy bank | Image credit: Andy Dean – stock.adobe.com
July 24th 2024

Oxygen Therapy for Fibrosing ILD Tied to Higher Costs, Mortality

Hayden E. Klein
Patients with fibrosing interstitial lung disease (ILD) who began supplemental oxygen therapy had triple the per patient per month ILD-related health care costs compared with those who did not.
Doctor using stethoscope to listen to lungs | Image credit: peopleimages.com – stock.adobe.com
July 13th 2024

How Diabetes Impacts Pulmonary Vascular Dysfunction and Fibrosis

Hayden E. Klein
Type 2 diabetes and prediabetes can both significantly impact pulmonary health, highlighting the need for early detection and intervention.
Stethoscope on stack of books | Image credit: ronstik – stock.adobe.com
July 10th 2024

Pulmonary Fibrosis, Macrophage Research Jumped Since 2020

Hayden E. Klein
The annual number of publications on macrophages and pulmonary fibrosis jumped during 2017 and 2020, with signs pointing to more focus on research in these fields.
IPF | Image credit: Sviatlana – stock.adobe.com
July 3rd 2024

Study Identifies P2RX7 as Key Player in IPF Pathogenesis, Therapy

Hayden E. Klein
Research highlighted the pivotal role of P2RX7 in driving inflammatory and fibrotic processes in idiopathic pulmonary fibrosis (IPF).
Person taking pills | Image credit: fizkes – stock.adobe.com
June 28th 2024

Many Patients With IPF Continue on Antifibrotics for 3 Years

Hayden E. Klein
However, registry data also showed no significant difference in transplant-free survival and time to pulmonary function decline between patients receiving antifibrotics vs placebo.
Clinical research graphic shaped like lightbulb | image credit: ArtemisDiana – stock.adobe.com
June 25th 2024

Report Highlights Advancements in 2024 Idiopathic Pulmonary Fibrosis Pipeline

Hayden E. Klein
More than 100 therapies for idiopathic pulmonary fibrosis are being developed across the globe.
Woman running hand through hair | Image credit: Alessandro Grandini – stock.adobe.com
June 12th 2024

Hair Metabolome May Help Diagnose Pulmonary Fibrosis

Hayden E. Klein
The proof-of-concept study also identified key metabolites that correlated with pulmonary fibrosis diagnosis and disease progression.
Image of lungs and a doctor with a vial labelled COVID-19 | Image credit: Image credit: Mongkolchon - stock.adobe.com
June 11th 2024

IPF and COPD Associated With Poor COVID-19 Outcomes

Kevin Kunzmann
Idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD) and other interstitial lung diseases are more significantly associated with poor 30-day outcomes from COVID-19 compared with asthma.
The Role of Lung Transplants in ILD Treatment
June 28th 2022

The Role of Lung Transplants in ILD Treatment

Dr Paul Noble comments on the role lung transplants play in ILD treatment.
Treatment Goals for Patients With ILD
June 14th 2022

Treatment Goals for Patients With ILD

Drs Noble and Highland explain the typical treatment goals physicians aim for when looking at ILD therapy options.
Lungs
August 6th 2020

Patients With IPF Are at Increased Risk for Multiple Cancers

Skylar Jeremias
Researchers found that patients with idiopathic pulmonary fibrosis (IPF) are at increased risk of developing several forms of cancer compared with the general population.
Multidisciplinary Collaborative Care Reduces Costs, Improves End-of-Life Care for Patients With IPF
July 25th 2020

Multidisciplinary Collaborative Care Reduces Costs, Improves End-of-Life Care for Patients With IPF

Jaime Rosenberg
In the last 3 months of life, health care costs were significantly lower for patients receiving multidisciplinary collaborative care than for patients receiving specialized care or nonspecialized care. The differences in costs were primarily driven by differences in hospitalizations and emergency department visits.
Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis
June 5th 2020

Patient-Reported Outcomes Linked to Mortality in Idiopathic Pulmonary Fibrosis

Rachel Lutz
The study sought to determine whether patient-reported outcomes are linked with death beyond clinical risk factors in patients with idiopathic pulmonary fibrosis (IPF).
<123>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo